Sanger Institute Sequences Two Cancer Genomes on Illumina and SOLiD Platforms
December 22, 2009
Sanger Institute Sequences Two Cancer Genomes on Illumina and SOLiD Platforms
The two papers indicate that whole-genome short-read sequencing technologies are becoming increasingly important for identifying cancer-causing genes that could eventually lead to better diagnosis and treatment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
January 25, 2011 / In Sequence - New Sequencing Platforms Drive Choice, Competition, Lawsuits in 2010
January 4, 2011 / In Sequence - 1K Genomes Project Publishes Initial Results, Aims to Sequence 2,500 Individuals on Illumina and SOLiD
November 2, 2010 / In Sequence - Cancer Sequencing with High Coverage on Two Platforms Improves Mutation Detection, Baylor Team Says
July 6, 2010 / In Sequence - USPTO Rejects Claims of Two Illumina Patents in Non-Final Action After Life Tech Reexam Request
May 11, 2010 / In Sequence